University researchers are expected to begin their study in the summer of 2024 and conclude in 2025
Optimi Health Corp. said March 26 it will supply MDMA to an Israeli university where researchers will study the drug’s potential to treat alcoholism.
Optimi, a psychedelics pharmaceutical manufacturer based in Canada, signed an agreement to provide the Institute for Psychedelic Research at Tel Aviv University with its MDMA formulation.
University researchers are expected to begin their study in the summer of 2024 and conclude in 2025, the company said.
Optimi has received the import permit from the provide the Institute for Psychedelic Research at Tel Aviv University and is in the process of obtaining its export permit from Health Canada.